Chondrial Therapeutics Holdings
Bala Cynwyd, US · Founded 2016 · Delaware LLC
Find your way into Chondrial Therapeutics Holdings
640 people in our graph share verified history with the Chondrial Therapeutics Holdings team — schools, employers, funds. One of them is your warm intro.
Lyle McCullochunlockedknows John Berman · together at Coopers and Lybrand (overlapped)
×3knows the team · via Coopers and Lybrand
×3knows the team · via The Wharton School
×2knows the team · via University of Pennsylvania
×3knows the team · via Cambridge Associates
Founders & leadership
NS
Noreen SchererinVice President Clinical OperationsShe has led clinical operations teams through drug development programs spanning early-stage trials to post-approval launch, with experience in rare and orphan disease indications and regulatory interactions across multiple jurisdictions.
DB
David BettounVice President Discovery and Preclinical Development
JJ
Jennifer JohanssonVice President Regulatory Affairs and Counsel, Secretary
JB
John BermaninVice President Finance and Operations, TreasurerJohn Berman has held finance and operations roles across pharmaceutical companies of varying scale, from early-stage divisions through integrated global operations, with experience in R&D and commercial finance functions.
CB
Carole Ben-MaimonPresident and Chief Executive Officer
RP
Ronald PayneNamed on SEC filing
BS
Bryan SendrowskiNamed on SEC filing
WS
William SlatteryNamed on SEC filing
Board
JL
Jonathan LeffBoard director
TH
Tom HamiltonChairman
Reported raises · per SEC filings
Form D private placements$29.2M disclosed across 2 of 3 rounds · 2016–2020
▶$15MofferedJan 2020 · BiotechnologyRule 506(b)
▶$15MofferedJan 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John BermanExecutive Officer
- Ronald Mark PayneDirector
- Jennifer JohanssonExecutive Officer
- Noreen SchererExecutive Officer
- Jonathan LeffDirector
- William SlatteryDirector
- Bryan SendrowskiDirector
- Tom HamiltonExecutive Officer, Director
- David BettounExecutive Officer
- Carole Ben-MaimonExecutive Officer, Director
- Offering amount
- $15M
- Minimum investment
- $5K
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$3.4MraisedDec 2019 · 7 investors · BiotechnologyRule 506(b)
▶$3.4MraisedDec 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tom HamiltonExecutive Officer, Director
- Jonathan LeffDirector
- Bryan SendrowskiDirector
- Carole Ben-MaimonExecutive Officer, Director
- Noreen SchererExecutive Officer
- William SlatteryDirector
- Ronald PayneDirector
- John BermanExecutive Officer
- Jennifer JohanssonExecutive Officer
- David BettounExecutive Officer
- Offering amount
- $10M
- Amount sold
- $3.4M
- Minimum investment
- $1
- First sale
- Nov 2019
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$25.8MraisedMay 2019 · 7 investors · BiotechnologyRule 506(b)
▶$25.8MraisedMay 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Noreen SchererExecutive Officer
- David BettounExecutive Officer
- Jennifer JohanssonExecutive Officer
- John BermanExecutive Officer
- Ronald PayneDirector
- Carole Ben-MaimonExecutive Officer, Director
- Tom HamiltonExecutive Officer, Director
- Bryan SendrowskiDirector
- William SlatteryDirector
- Jonathan LeffDirector
- Offering amount
- $35.8M
- Amount sold
- $25.8M
- Minimum investment
- $1
- First sale
- Nov 2016
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Chondrial Therapeutics Holdings raised?
- Chondrial Therapeutics Holdings has disclosed $29.2M raised across 2 of its 3 known rounds.
- Where is Chondrial Therapeutics Holdings headquartered?
- Chondrial Therapeutics Holdings is headquartered in Bala Cynwyd, US.